Cargando…

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus(®) Insulin Glargine

INTRODUCTION: We compared insulin antibody response (IAR) profiles in patients with type 1 diabetes (T1D) or type 2 diabetes (T2D) who received LY2963016 insulin glargine (LY IGlar) or Lantus(®) insulin glargine (IGlar) and evaluated the potential relationship between higher IARs and clinical and sa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ilag, Liza L., Costigan, Timothy M., Deeg, Mark A., Pollom, Robyn K., Chang, Curtis L., Konrad, Robert J., Prince, Melvin J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446380/ https://www.ncbi.nlm.nih.gov/pubmed/28361463 http://dx.doi.org/10.1007/s13300-017-0253-8

Ejemplares similares

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
por: Ilag, L. L., et al.
Publicado: (2016)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
por: Wang, Weimin, et al.
Publicado: (2022)

Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
por: Hadjiyianni, I., et al.
Publicado: (2016)

Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus(®) Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation
por: Nishiyama, Hiroshi, et al.
Publicado: (2018)

Lilly Insulin Glargine Versus Lantus(®) in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5)
por: Pollom, Robyn K., et al.
Publicado: (2019)

Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open‐label, controlled trial
por: Feng, Wenhuan, et al.
Publicado: (2021)

Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus(®)): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial
por: Yan, Xiang, et al.
Publicado: (2022)

Comment on: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
por: Perfetti, Riccardo
Publicado: (2018)

Similar Efficacy and Safety of Basaglar(®) and Lantus(®) in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study
por: Pollom, Robyn K., et al.
Publicado: (2018)

Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus(®) in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints
por: Wang, Yiya, et al.
Publicado: (2022)

Single‐dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK‐1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects
por: Crutchlow, Michael F., et al.
Publicado: (2017)

Switching from biosimilar (Basalin) to originator (Lantus) insulin glargine is effective in Chinese patients with diabetes mellitus: a retrospective chart review
por: Hu, Xia, et al.
Publicado: (2018)

Which Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study
por: Bu, Shi, et al.
Publicado: (2017)

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes
por: Bergenstal, Richard M., et al.
Publicado: (2012)

Lilly Insulin Glargine Versus Lantus(®) in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study
por: Mohan, Viswanathan, et al.
Publicado: (2019)

Real-World Impact of Switching From Insulin Glargine (Lantus(®)) to Basaglar(®) and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia
por: AlRuthia, Yazed, et al.
Publicado: (2022)

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study
por: Rosenstock, Julio, et al.
Publicado: (2013)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials
por: Rosenstock, Julio, et al.
Publicado: (2016)

Response to Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes. Diabetes Care 2012;35:2140–2147
por: Bergenstal, Richard M., et al.
Publicado: (2013)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

A case of hypersensitivity to soluble and isophane insulins but not to insulin glargine
por: Belhekar, Mahesh N., et al.
Publicado: (2015)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Protocol to Assess the Biological Activity of Insulin Glargine, Insulin Lispro, and Insulin Aspart In Vitro
por: Garige, Mamatha, et al.
Publicado: (2023)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Characteristics of insulin-Naïve people with type 2 diabetes who successfully respond to insulin glargine U100 after 24 weeks of treatment: a meta-analysis of individual participant data from 3 randomized clinical trials
por: Cummings, M. H., et al.
Publicado: (2018)

Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-I, and Human Insulin on Insulin and IGF-I Receptor Signaling
por: Varewijck, Aimee J., et al.
Publicado: (2013)

Glargine insulin: an alternative to regular insulin for glycemic control in critically ill patients
por: Bhattacharyya, M, et al.
Publicado: (2007)

Basal insulin peglispro versus insulin glargine in insulin‐naïve type 2 diabetes: IMAGINE 2 randomized trial
por: Davies, M. J., et al.
Publicado: (2016)

Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes
por: Home, P D, et al.
Publicado: (2012)

Insulin Glargine: A Reevaluation of Rodent Carcinogenicity Findings
por: Stammberger, Ingo, et al.
Publicado: (2012)

A Salutary Tale—Glargine insulin and cancer risk
por: Boyle, Peter
Publicado: (2009)

Insulin Glargine and Acarbose in the treatment of elderly patients with diabetes
por: Li, Jing, et al.
Publicado: (2019)

Insulin-glargine/norepinephrine: Lack of efficacy: case report
Publicado: (2022)

Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats
por: Tennagels, N., et al.
Publicado: (2013)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
por: Davis, Sondra, et al.
Publicado: (2017)

The Role of Insulin Glargine and Human Insulin in the Regulation of Thyroid Proliferation Through Mitogenic Signaling
por: Sheng, Xiaoli, et al.
Publicado: (2019)

Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study
por: Takeishi, Soichi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_esqp5b1r5mnvare99gn93h2skp